UPDATED SURVIVAL RESULTS FROM A RANDOMIZED, DOSE-RANGING PHASE II STUDY OF NIVOLUMAB (NIVO) IN METASTATIC RENAL CELL CARCINOMA (MRCC)
Publication
, Journal Article
Plimack, ER; Hammers, HJ; Rini, BI; McDermott, DF; Redman, BG; Kuzel, TM; Harrison, MR; Vaishampayan, UN; Drabkin, HA; George, S; Logan, TF ...
Published in: Asia-Pacific Journal of Clinical Oncology
2015
Duke Scholars
Published In
Asia-Pacific Journal of Clinical Oncology
EISSN
1743-7563
ISSN
1743-7555
Publication Date
2015
Volume
11
Start / End Page
129 / 129
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Plimack, E. R., Hammers, H. J., Rini, B. I., McDermott, D. F., Redman, B. G., Kuzel, T. M., … Motzer, R. J. (2015). UPDATED SURVIVAL RESULTS FROM A RANDOMIZED, DOSE-RANGING PHASE II STUDY OF NIVOLUMAB (NIVO) IN METASTATIC RENAL CELL CARCINOMA (MRCC). Asia-Pacific Journal of Clinical Oncology, 11, 129–129.
Plimack, Elizabeth R., Hans J. Hammers, Brian I. Rini, David F. McDermott, Bruce G. Redman, Timothy M. Kuzel, Michael R. Harrison, et al. “UPDATED SURVIVAL RESULTS FROM A RANDOMIZED, DOSE-RANGING PHASE II STUDY OF NIVOLUMAB (NIVO) IN METASTATIC RENAL CELL CARCINOMA (MRCC).” Asia-Pacific Journal of Clinical Oncology 11 (2015): 129–129.
Plimack ER, Hammers HJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, et al. UPDATED SURVIVAL RESULTS FROM A RANDOMIZED, DOSE-RANGING PHASE II STUDY OF NIVOLUMAB (NIVO) IN METASTATIC RENAL CELL CARCINOMA (MRCC). Asia-Pacific Journal of Clinical Oncology. 2015;11:129–129.
Plimack, Elizabeth R., et al. “UPDATED SURVIVAL RESULTS FROM A RANDOMIZED, DOSE-RANGING PHASE II STUDY OF NIVOLUMAB (NIVO) IN METASTATIC RENAL CELL CARCINOMA (MRCC).” Asia-Pacific Journal of Clinical Oncology, vol. 11, 2015, pp. 129–129.
Plimack ER, Hammers HJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, Margolin KA, Xu L-A, Waxman IM, Motzer RJ. UPDATED SURVIVAL RESULTS FROM A RANDOMIZED, DOSE-RANGING PHASE II STUDY OF NIVOLUMAB (NIVO) IN METASTATIC RENAL CELL CARCINOMA (MRCC). Asia-Pacific Journal of Clinical Oncology. 2015;11:129–129.
Published In
Asia-Pacific Journal of Clinical Oncology
EISSN
1743-7563
ISSN
1743-7555
Publication Date
2015
Volume
11
Start / End Page
129 / 129
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis